The global colorectal cancer market is expected to grow from US$ 18,619.3 million in 2022 to US$ 24,078.5 million by 2028.
Factors such as the increasing prevalence of colorectal cancer, product launches, and benefits offered by generic drugs are driving the growth of the global colorectal cancer market. However, pricing pressure on drug manufacturers is hampering the global colorectal cancer market growth.
Colorectal cancer, also known as bowel cancer, colon cancer, or rectal cancer, is any form of cancer that affects the colon and the rectum. Colon and rectal cancer are often grouped together as many features are common in them. The majority of colorectal cancers generally develop over time from adenomatous (precancerous) polyps. Colorectal cancer may be benign, or non-cancerous, or malignant. Some of the risk factors for colorectal cancer involve a family history of colon or rectal cancer, diet, alcohol intake, smoking and inflammatory bowel disease. The symptoms shown by the patients who have colon cancer include changes in bowel habits, diarrhea or constipation, blood in stools that make it look black. Colorectal cancer can be treated with chemotherapy, radiotherapy, and surgery.
The increasing medical tourism and the growing pharmaceutical industry in emerging countries are expected to boost the global colorectal cancer market growth. According to India Brand Equity Foundation (IBEF) statistics in April 2019, India is the largest provider of generic drugs worldwide. The Indian pharmaceutical industry supplies ~40% of generic demand in the US, with ~50% of the global demand for multiple vaccines and 25% of all medicines in the UK. The pharmaceutical sector in India is expected to grow from US$ 42 billion in 2021 to US$ 55 billion by 2025; it is estimated to register at a CAGR of 37% from 2020 to 2025. Moreover, India has a huge pool of scientists and engineers having the potential to grow the healthcare industry remarkably.
Major market players focus on emerging markets such as Singapore and China as they have many colorectal cancer patients and growing medical tourism. As per the Australian Institute of Health and Welfare, over ~15,540 new cases of colorectal cancer were diagnosed in 2021. Moreover, as per the Malaysia Healthcare Travel Council, in 2019, over 1.22 million healthcare travelers visited Malaysia for healthcare purposes. The low cost of treatment and incorporation of advanced technologies to provide less waiting time for procedures in Asia Pacific are likely to boost the number of surgeries. This ultimately increases the demand for colorectal cancer diagnostics and treatment.
Many key market players are involved in manufacturing a wide range of drugs and diagnostic tests that help in reducing the burden of colorectal cancer. For instance, in June 2021, Bristol Myers Squibb announced the approval of Opdivo plus Yervoy by the European Commission (EC) for the treatment of adult patients with microsatellite instability-high (MSI-H) metastatic colorectal cancer. In July 2020, Taiho Pharmaceutical Co., Ltd. launched LONSURF, its anticancer agent, for the treatment of patients with metastatic colorectal cancer. With the launch of this product in China, the company expected that Lonsurf would offer a broader contribution to patients and medical institutions as a new treatment option for patients with colorectal cancer. Furthermore, inorganic developments by the key players of the global colorectal cancer market will also help the market to grow. For instance, Epigenomics AG announced its Next Generation Liquid Biopsy Test for colorectal cancer screening and planned to appeal the National Coverage Determination (NCD) decision in 2021. Thus, the constant developments and new product launches in colorectal cancer diagnostics and therapeutics are driving the global colorectal cancer market growth.
The global colorectal cancer market is bifurcated into modality and end user. Based on modality, the global colorectal cancer market is segmented into diagnosis type, therapy type, and imaging type. The diagnosis type segment is estimated to account for the largest market share and is expected to register the highest CAGR during the forecast period. Colorectal cancer or CRC is the most frequent human malignant neoplasms. The diagnostics emphasize the need for early recognition of neoplasms in the asymptomatic or precancerous stage. Therefore, early recognition is essential in patients with acute symptoms and adverse course of the disease. The diagnosis type segment holds the largest share of the global colorectal cancer market in 2022. The diagnosis type is further segmented into immunohistochemistry, stool test, flexible sigmoidoscopy, colonoscopy, CEA test, and others. Moreover, the stool test segment is anticipated to register the highest CAGR in the market during the forecast period. Stool-based tests are noninvasive for colorectal cancer screening options. For this test, no special diet or bowel preparation is required. Stool-based tests are recommended for patients with an average risk for colorectal cancer or no personal history. Further, guaiac-based fecal occult blood test (gFOBT) and fecal immunochemical test (FIT) are the noninvasive tests practiced to find blood in the stool that may be a symptom of cancer or large polyps. These tests can be taken at home with a kit after following instructions. Another type of noninvasive test is Stool DNA testing, which looks for certain DNA or gene changes that often get into the stool, which can be a sign of cancer if a stool DNA test results in abnormal. Fecal occult blood testing (FOBT) is the most widely prescribed screening test for CRC as it is simple, noninvasive, and has been demonstrated to reduce the chances of death due to CRC. For instance, Clinical Genomics Technologies Pty Ltd offers InSure ONE (Fecal Immunochemical testing) for detecting blood in the stool, which helps to diagnose CRC.
The World Health Organization (WHO), American Cancer Society, Centers for Disease Control and Prevention (CDC), and GLOBOCAN: Global Cancer Observatory are among the primary and secondary sources referred to while preparing the report on the global colorectal cancer market.
Factors such as the increasing prevalence of colorectal cancer, product launches, and benefits offered by generic drugs are driving the growth of the global colorectal cancer market. However, pricing pressure on drug manufacturers is hampering the global colorectal cancer market growth.
Colorectal cancer, also known as bowel cancer, colon cancer, or rectal cancer, is any form of cancer that affects the colon and the rectum. Colon and rectal cancer are often grouped together as many features are common in them. The majority of colorectal cancers generally develop over time from adenomatous (precancerous) polyps. Colorectal cancer may be benign, or non-cancerous, or malignant. Some of the risk factors for colorectal cancer involve a family history of colon or rectal cancer, diet, alcohol intake, smoking and inflammatory bowel disease. The symptoms shown by the patients who have colon cancer include changes in bowel habits, diarrhea or constipation, blood in stools that make it look black. Colorectal cancer can be treated with chemotherapy, radiotherapy, and surgery.
The increasing medical tourism and the growing pharmaceutical industry in emerging countries are expected to boost the global colorectal cancer market growth. According to India Brand Equity Foundation (IBEF) statistics in April 2019, India is the largest provider of generic drugs worldwide. The Indian pharmaceutical industry supplies ~40% of generic demand in the US, with ~50% of the global demand for multiple vaccines and 25% of all medicines in the UK. The pharmaceutical sector in India is expected to grow from US$ 42 billion in 2021 to US$ 55 billion by 2025; it is estimated to register at a CAGR of 37% from 2020 to 2025. Moreover, India has a huge pool of scientists and engineers having the potential to grow the healthcare industry remarkably.
Major market players focus on emerging markets such as Singapore and China as they have many colorectal cancer patients and growing medical tourism. As per the Australian Institute of Health and Welfare, over ~15,540 new cases of colorectal cancer were diagnosed in 2021. Moreover, as per the Malaysia Healthcare Travel Council, in 2019, over 1.22 million healthcare travelers visited Malaysia for healthcare purposes. The low cost of treatment and incorporation of advanced technologies to provide less waiting time for procedures in Asia Pacific are likely to boost the number of surgeries. This ultimately increases the demand for colorectal cancer diagnostics and treatment.
Many key market players are involved in manufacturing a wide range of drugs and diagnostic tests that help in reducing the burden of colorectal cancer. For instance, in June 2021, Bristol Myers Squibb announced the approval of Opdivo plus Yervoy by the European Commission (EC) for the treatment of adult patients with microsatellite instability-high (MSI-H) metastatic colorectal cancer. In July 2020, Taiho Pharmaceutical Co., Ltd. launched LONSURF, its anticancer agent, for the treatment of patients with metastatic colorectal cancer. With the launch of this product in China, the company expected that Lonsurf would offer a broader contribution to patients and medical institutions as a new treatment option for patients with colorectal cancer. Furthermore, inorganic developments by the key players of the global colorectal cancer market will also help the market to grow. For instance, Epigenomics AG announced its Next Generation Liquid Biopsy Test for colorectal cancer screening and planned to appeal the National Coverage Determination (NCD) decision in 2021. Thus, the constant developments and new product launches in colorectal cancer diagnostics and therapeutics are driving the global colorectal cancer market growth.
The global colorectal cancer market is bifurcated into modality and end user. Based on modality, the global colorectal cancer market is segmented into diagnosis type, therapy type, and imaging type. The diagnosis type segment is estimated to account for the largest market share and is expected to register the highest CAGR during the forecast period. Colorectal cancer or CRC is the most frequent human malignant neoplasms. The diagnostics emphasize the need for early recognition of neoplasms in the asymptomatic or precancerous stage. Therefore, early recognition is essential in patients with acute symptoms and adverse course of the disease. The diagnosis type segment holds the largest share of the global colorectal cancer market in 2022. The diagnosis type is further segmented into immunohistochemistry, stool test, flexible sigmoidoscopy, colonoscopy, CEA test, and others. Moreover, the stool test segment is anticipated to register the highest CAGR in the market during the forecast period. Stool-based tests are noninvasive for colorectal cancer screening options. For this test, no special diet or bowel preparation is required. Stool-based tests are recommended for patients with an average risk for colorectal cancer or no personal history. Further, guaiac-based fecal occult blood test (gFOBT) and fecal immunochemical test (FIT) are the noninvasive tests practiced to find blood in the stool that may be a symptom of cancer or large polyps. These tests can be taken at home with a kit after following instructions. Another type of noninvasive test is Stool DNA testing, which looks for certain DNA or gene changes that often get into the stool, which can be a sign of cancer if a stool DNA test results in abnormal. Fecal occult blood testing (FOBT) is the most widely prescribed screening test for CRC as it is simple, noninvasive, and has been demonstrated to reduce the chances of death due to CRC. For instance, Clinical Genomics Technologies Pty Ltd offers InSure ONE (Fecal Immunochemical testing) for detecting blood in the stool, which helps to diagnose CRC.
The World Health Organization (WHO), American Cancer Society, Centers for Disease Control and Prevention (CDC), and GLOBOCAN: Global Cancer Observatory are among the primary and secondary sources referred to while preparing the report on the global colorectal cancer market.
Table of Contents
1. Introduction1.1 Scope of the Study
1.2 Report Guidance
1.3 Market Segmentation
1.3.1 Global Colorectal Cancer Market - By Modality
1.3.2 Global Colorectal Cancer Market - By End User
1.3.3 Global Colorectal Cancer Market - By Geography
2. Global Colorectal Cancer Market - Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Global Colorectal Cancer - Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Colorectal Cancer Market - North America PEST Analysis
4.2.2 Colorectal Cancer Market - Europe PEST Analysis
4.2.3 Colorectal Cancer Market - Asia Pacific PEST Analysis
4.2.4 Colorectal Cancer Market - Middle East & Africa PEST Analysis
4.2.5 Colorectal Cancer Market - South And Central America PEST Analysis
4.3 Expert Opinion
5. Global Colorectal Cancer Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing Prevalence of Colorectal Cancer
5.1.2 New Product Launches
5.1.3 Benefits Offered by Generic Drugs
5.2 Market Restraints
5.2.1 Pricing Pressure on Drug Manufacturers
5.3 Market Opportunities
5.3.1 Growing Pharmaceutical Industry in Emerging Economies
5.4 Future Trends
5.4.1 Inclination Toward Personalized Medicine
5.5 Impact Analysis
6. Global Colorectal Cancer Market - Global Analysis
6.1 Global Colorectal Cancer Market Revenue Forecast and Analysis
6.1.1 Overview
6.1.2 Global Colorectal Cancer Market, By Geography - Forecasts And Analysis
6.1.3 Global Colorectal Cancer Market - Market Potential Analysis, By Region
6.2 Company Analysis
6.2.1 Market Share Analysis of Key Players in Global Colorectal Cancer Market (2021)
6.2.2 Comparative Company Analysis
6.2.3 Growth Strategy Analysis
6.2.4 Performance of Key Players
6.2.4.1 Abbott
6.2.4.2 F. Hoffmann-La Roche AG
7. Global Colorectal Cancer Market Analysis - By Modality
7.1 Overview
7.2 Global Colorectal Cancer Market Revenue Share, By Modality 2022 & 2028 (%)
7.3 Diagnosis Type
7.3.1 Overview
7.3.2 Diagnosis Type: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
7.3.3 Immunohistochemistry
7.3.3.1 Overview
7.3.3.2 Immunohistochemistry: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
7.3.4 Stool Test
7.3.4.1 Overview
7.3.4.2 Stool Test: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
7.3.5 Flexible Sigmoidoscopy
7.3.5.1 Overview
7.3.5.2 Flexible Sigmoidoscopy: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
7.3.6 Colonoscopy
7.3.6.1 Overview
7.3.6.2 Colonoscopy: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
7.3.7 CEA Test
7.3.7.1 Overview
7.3.7.2 CEA Test: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
7.3.8 Other Test
7.3.8.1 Overview
7.3.8.2 Other Test: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
7.4 Therapy Type
7.4.1 Overview
7.4.2 Global Therapy Type: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
7.4.3 Chemotherapy
7.4.3.1 Overview
7.4.3.2 Chemotherapy: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
7.4.3.3 Alkylating Agent
7.4.3.3.1 Overview
7.4.3.3.2 Alkylating Agent: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
7.4.3.4 Antimetabolites
7.4.3.4.1 Antimetabolites: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
7.4.3.5 Others
7.4.3.5.1 Others: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
7.4.4 Immunotherapy
7.4.4.1 Overview
7.4.4.2 Immunotherapy: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
7.4.4.3 Panitumumab
7.4.4.3.1 Overview
7.4.4.3.2 Panitumumab: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
7.4.4.4 Cetuximab
7.4.4.4.1 Overview
7.4.4.4.2 Cetuximab: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
7.4.4.5 Bevacizumab
7.4.4.5.1 Overview
7.4.4.5.2 Bevacizumab: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
7.4.4.6 Others
7.4.4.6.1 Overview
7.4.4.6.2 Others: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
7.4.5 Chemoprotectant
7.4.5.1 Overview
7.4.5.2 Chemoprotectant: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
7.4.6 Others
7.4.6.1 Overview
7.4.6.2 Others: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
7.5 Imaging Type
7.5.1 Overview
7.5.2 Global Imaging Type: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
7.5.3 Computed Tomography (CT)
7.5.3.1 Overview
7.5.3.2 Computed Tomography (CT): Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
7.5.4 Magnetic Resonance Imaging (MRI)
7.5.4.1 Overview
7.5.4.2 Magnetic Resonance Imaging (MRI): Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
7.5.5 Others
7.5.5.1 Overview
7.5.5.2 Others: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
8. Global Colorectal Cancer Market Revenue and Forecast To 2028 - By End User
8.1 Overview
8.2 Global Colorectal Cancer Market Revenue Share, By End User 2022 & 2028 (%)
8.3 Hospitals
8.3.1 Overview
8.3.2 Hospitals: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
8.4 Diagnostic and Research Laboratories
8.4.1 Overview
8.4.2 Diagnostic and Research Laboratories: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
9. Global Colorectal Cancer Market Revenue and Forecast to 2028 - Geographical Analysis
9.1 North America: Colorectal Cancer Market
9.1.1 Overview
9.1.2 North America: Colorectal Cancer Market Revenue and Forecast to 2028 (US$ Million)
9.1.3 North America: Colorectal Cancer Market - Revenue and Forecast to 2028, By Modality (US$ Million)
9.1.3.1 North America: Colorectal Cancer Market, by Diagnosis Type - 2019 - 2028 (US$ Million)
9.1.3.2 North America: Colorectal Cancer Market, by Therapy Type - 2019 - 2028 (US$ Million)
9.1.3.2.1 North America: Colorectal Cancer Market, by Chemotherapy - 2019 - 2028 (US$ Million)
9.1.3.2.2 North America: Colorectal Cancer Market, by Immunotherapy - 2019 - 2028 (US$ Million)
9.1.3.3 North America: Colorectal Cancer Market, by Imaging Type - 2019 - 2028 (US$ Million)
9.1.4 North America: Colorectal Cancer Market Revenue and Forecast To 2028, By End Users (US$ Million)
9.1.5 North America: Colorectal Cancer Market, by Country, 2022 & 2028 (%)
9.1.5.1 US: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
9.1.5.1.1 US: Colorectal Cancer Market Revenue and Forecast to 2028 (US$ Million)
9.1.5.1.2 US: Colorectal Cancer Market - Revenue and Forecast to 2028, By Modality (US$ Million)
9.1.5.1.2.1 US: Colorectal Cancer Market, by Diagnosis Type - 2019 - 2028 (US$ Million)
9.1.5.1.2.2 US: Colorectal Cancer Market, by Therapy Type - 2019- 2028 (US$ Million)
9.1.5.1.2.2.1. US: Colorectal Cancer Market, by Chemotherapy - 2019-2028 (US$ Million)
9.1.5.1.2.2.2. US: Colorectal Cancer Market, by Immunotherapy - 2019- 2028 (US$ Million)
9.1.5.1.2.3 US: Colorectal Cancer Market, by Imaging Type - 2019 - 2028 (US$ Million)
9.1.5.1.3 US: Colorectal Cancer Market Revenue and Forecast To 2028, By End Users (US$ Million)
9.1.5.2 Canada: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
9.1.5.2.1 Canada: Colorectal Cancer Market Revenue and Forecast to 2028 (US$ Million)
9.1.5.2.2 Canada: Colorectal Cancer Market - Revenue and Forecast to 2028, By Modality (US$ Million)
9.1.5.2.2.1 Canada: Colorectal Cancer Market, by Diagnosis Type - 2019 - 2028 (US$ Million)
1.1.5.2.1.1 Canada: Colorectal Cancer Market, by Therapy Type - 2019- 2028 (US$ Million)
9.1.5.2.2.1.1. Canada: Colorectal Cancer Market, by Chemotherapy - 2019-2028 (US$ Million)
9.1.5.2.2.1.2. Canada: Colorectal Cancer Market, by Immunotherapy - 2019- 2028 (US$ Million)
9.1.5.2.2.2 Canada: Colorectal Cancer Market, by Imaging Type - 2019 - 2028 (US$ Million)
9.1.5.2.3 Canada: Colorectal Cancer Market Revenue and Forecast To 2028, By End Users (US$ Million)
9.1.5.3 Mexico: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
9.1.5.3.1 Mexico: Colorectal Cancer Market Revenue and Forecast to 2028 (US$ Million)
9.1.5.3.2 Mexico: Colorectal Cancer Market - Revenue and Forecast to 2028, By Modality (US$ Million)
9.1.5.3.2.1 Mexico: Colorectal Cancer Market, by Diagnosis Type - 2019 - 2028 (US$ Million)
9.1.5.3.2.2 Mexico: Colorectal Cancer Market, by Therapy Type - 2019- 2028 (US$ Million)
9.1.5.3.2.2.1. Mexico: Colorectal Cancer Market, by Chemotherapy - 2019-2028 (US$ Million)
9.1.5.3.2.2.2. Mexico: Colorectal Cancer Market, by Immunotherapy - 2019- 2028 (US$ Million)
9.1.5.3.2.3 Mexico: Colorectal Cancer Market, by Imaging Type - 2019 - 2028 (US$ Million)
9.1.5.3.3 Mexico: Colorectal Cancer Market - Revenue and Forecast To 2028, By End Users (US$ Million)
9.2 Europe: Colorectal Cancer Market
9.2.1 Overview
9.2.2 Europe: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
9.2.3 Europe: Colorectal Cancer Market - Revenue and Forecast to 2028, By Modality (US$ Million)
9.2.3.1 Europe: Colorectal Cancer Market, by Diagnosis Type - 2019 - 2028 (US$ Million)
9.2.3.2 Europe: Colorectal Cancer Market, by Therapy Type - 2019- 2028 (US$ Million)
9.2.3.2.1 Europe: Colorectal Cancer Market, by Chemotherapy - 2019- 2028 (US$ Million)
9.2.3.2.2 Europe: Colorectal Cancer Market, by Immunotherapy - 2019- 2028 (US$ Million)
9.2.3.3 Europe: Colorectal Cancer Market, by Imaging Type - 2019 - 2028 (US$ Million)
9.2.4 Europe: Colorectal Cancer Market Revenue and Forecast To 2028, By End Users (US$ Million)
9.2.5 Europe: Colorectal Cancer Market, by Country, 2022 & 2028 (%)
9.2.5.1 Germany: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
9.2.5.1.1 Germany: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
9.2.5.1.2 Germany: Colorectal Cancer Market - Revenue and Forecast to 2028, By Modality (US$ Million)
9.2.5.1.2.1 Germany: Colorectal Cancer Market, by Diagnosis Type - 2019 - 2028 (US$ Million)
9.2.5.1.2.2 Germany: Colorectal Cancer Market, by Therapy Type - 2019- 2028 (US$ Million)
9.2.5.1.2.2.1. Germany: Colorectal Cancer Market, by Chemotherapy - 2019- 2028 (US$ Million)
9.2.5.1.2.2.2. Germany: Colorectal Cancer Market, by Immunotherapy - 2019- 2028 (US$ Million)
9.2.5.1.2.3 Germany: Colorectal Cancer Market, by Imaging Type - 2019 - 2028 (US$ Million)
9.2.5.1.3 Germany: Colorectal Cancer Market Revenue and Forecast To 2028, By End Users (US$ Million)
9.2.5.2 France: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
9.2.5.2.1 France: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
9.2.5.2.2 France: Colorectal Cancer Market - Revenue and Forecast to 2028, By Modality (US$ Million)
9.2.5.2.2.1 France: Colorectal Cancer Market, by Diagnosis Type - 2019 - 2028 (US$ Million)
9.2.5.2.2.2 France: Colorectal Cancer Market, by Therapy Type - 2019- 2028 (US$ Million)
9.2.5.2.2.2.1. France: Colorectal Cancer Market, by Chemotherapy - 2019- 2028 (US$ Million)
9.2.5.2.2.2.2. France: Colorectal Cancer Market, by Immunotherapy - 2019- 2028 (US$ Million)
9.2.5.2.2.3 France: Colorectal Cancer Market, by Imaging Type - 2019 - 2028 (US$ Million)
9.2.5.2.3 France: Colorectal Cancer Market Revenue and Forecast To 2028, By End Users (US$ Million)
9.2.5.3 UK: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
9.2.5.3.1 UK: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
9.2.5.3.2 UK: Colorectal Cancer Market - Revenue and Forecast to 2028, By Modality (US$ Million)
9.2.5.3.2.1 UK: Colorectal Cancer Market, by Diagnosis Type - 2019 - 2028 (US$ Million)
9.2.5.3.2.2 UK: Colorectal Cancer Market, by Therapy Type - 2019- 2028 (US$ Million)
9.2.5.3.2.2.1. UK: Colorectal Cancer Market, by Chemotherapy - 2019- 2028 (US$ Million)
9.2.5.3.2.2.2. UK: Colorectal Cancer Market, by Immunotherapy - 2019- 2028 (US$ Million)
9.2.5.3.2.3 UK: Colorectal Cancer Market, by Imaging Type - 2019 - 2028 (US$ Million)
9.2.5.3.3 UK: Colorectal Cancer Market Revenue and Forecast To 2028, By End Users (US$ Million)
9.2.5.4 Italy: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
9.2.5.4.1 Italy: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
9.2.5.4.2 Italy: Colorectal Cancer Market - Revenue and Forecast to 2028, By Modality (US$ Million)
9.2.5.4.2.1 Italy: Colorectal Cancer Market, by Diagnosis Type - 2019 - 2028 (US$ Million)
9.2.5.4.2.2 Italy: Colorectal Cancer Market, by Therapy Type - 2019- 2028 (US$ Million)
9.2.5.4.2.2.1. Italy: Colorectal Cancer Market, by Chemotherapy - 2019- 2028 (US$ Million)
9.2.5.4.2.2.2. Italy: Colorectal Cancer Market, by Immunotherapy - 2019- 2028 (US$ Million)
9.2.5.4.2.3 Italy: Colorectal Cancer Market, by Imaging Type - 2019 - 2028 (US$ Million)
9.2.5.4.3 Italy: Colorectal Cancer Market Revenue and Forecast To 2028, By End Users (US$ Million)
9.2.5.5 Spain: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
9.2.5.5.1 Spain: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
9.2.5.5.2 Spain: Colorectal Cancer Market - Revenue and Forecast to 2028, By Modality (US$ Million)
9.2.5.5.2.1 Spain: Colorectal Cancer Market, by Diagnosis Type - 2019 - 2028 (US$ Million)
9.2.5.5.2.2 Spain: Colorectal Cancer Market, by Therapy Type - 2019- 2028 (US$ Million)
9.2.5.5.2.2.1. Spain: Colorectal Cancer Market, by Chemotherapy - 2019- 2028 (US$ Million)
9.2.5.5.2.2.2. Spain: Colorectal Cancer Market, by Immunotherapy - 2019- 2028 (US$ Million)
9.2.5.5.2.3 Spain: Colorectal Cancer Market, by Imaging Type - 2019 - 2028 (US$ Million)
9.2.5.5.3 Spain: Colorectal Cancer Market Revenue and Forecast To 2028, By End Users (US$ Million)
9.2.5.6 Rest of Europe: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
9.2.5.6.1 Rest of Europe: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
9.2.5.6.2 Rest of Europe: Colorectal Cancer Market - Revenue and Forecast to 2028, By Modality (US$ Million)
9.2.5.6.2.1 Rest of Europe: Colorectal Cancer Market, by Diagnosis Type - 2019 - 2028 (US$ Million)
9.2.5.6.2.2 Rest of Europe: Colorectal Cancer Market, by Therapy Type - 2019- 2028 (US$ Million)
9.2.5.6.2.2.1. Rest of Europe: Colorectal Cancer Market, by Chemotherapy - 2019- 2028 (US$ Million)
9.2.5.6.2.2.2. Rest of Europe: Colorectal Cancer Market, by Immunotherapy - 2019- 2028 (US$ Million)
9.2.5.6.2.3 Rest of Europe: Colorectal Cancer Market, by Imaging Type - 2019 - 2028 (US$ Million)
9.2.5.6.3 Rest of Europe: Colorectal Cancer Market Revenue and Forecast To 2028, By End Users (US$ Million)
9.3 Asia Pacific Colorectal Cancer Market Revenue and Forecast to 2028
9.3.1 Overview
9.3.2 Asia Pacific: Colorectal Cancer Market Revenue And Forecasts To 2028 (US$ Million)
9.3.3 Asia Pacific: Colorectal Cancer Market - Revenue and Forecast to 2028, By Modality (US$ Million)
9.3.3.1 Asia Pacific: Colorectal Cancer Market, by Diagnosis Type - 2019 - 2028 (US$ Million)
9.3.3.2 Asia Pacific Therapy Type Market Revenue and Forecasts to 2028, By Therapy Type (US$ Million)
9.3.3.2.1 Asia Pacific Chemotherapy Market Revenue and Forecasts to 2028, By Chemotherapy (US$ Million)
9.3.3.2.2 Asia Pacific Immunotherapy Market Revenue and Forecasts to 2028, By Immunotherapy (US$ Million)
9.3.3.3 Asia Pacific Imaging Type Market Revenue and Forecasts to 2028, By Imaging Type (US$ Million)
9.3.4 Asia Pacific: Colorectal Cancer Market Revenue and Forecast To 2028, By End Users (US$ Million)
9.3.5 Asia Pacific Colorectal Cancer Market Revenue and Forecasts to 2028, By Country (%)
9.3.5.1 China Colorectal Cancer Market Revenue And Forecasts To 2028 (US$ Million)
9.3.5.1.1 China Colorectal Cancer Market Revenue And Forecasts To 2028 (US$ Million)
9.3.5.1.2 China: Colorectal Cancer Market - Revenue and Forecast to 2028, By Modality (US$ Million)
9.3.5.1.2.1 China: Colorectal Cancer Market, by Diagnosis Type - 2019 - 2028 (US$ Million)
9.3.5.1.2.2 China: Colorectal Cancer Market, by Therapy Type - 2019- 2028 (US$ Million)
9.3.5.1.2.2.1. China: Colorectal Cancer Market, by Chemotherapy - 2019- 2028 (US$ Million)
9.3.5.1.2.2.2. China: Colorectal Cancer Market, by Immunotherapy - 2019- 2028 (US$ Million)
9.3.5.1.2.3 China: Colorectal Cancer Market, by Imaging Type - 2019- 2028 (US$ Million)
9.3.5.1.3 China: Colorectal Cancer Market Revenue and Forecast To 2028, By End Users (US$ Million)
9.3.5.2 Japan Colorectal Cancer Market Revenue And Forecasts To 2028 (US$ Million)
9.3.5.2.1 Japan Colorectal Cancer Market Revenue And Forecasts To 2028 (US$ Million)
9.3.5.2.2 Japan: Colorectal Cancer Market - Revenue and Forecast to 2028, By Modality (US$ Million)
9.3.5.2.2.1 Japan: Colorectal Cancer Market, by Diagnosis Type - 2019 - 2028 (US$ Million)
9.3.5.2.2.2 Japan: Colorectal Cancer Market, by Therapy Type - 2019- 2028 (US$ Million)
9.3.5.2.2.2.1. Japan: Colorectal Cancer Market, by Chemotherapy - 2019- 2028 (US$ Million)
9.3.5.2.2.2.2. Japan: Colorectal Cancer Market, by Immunotherapy - 2019- 2028 (US$ Million)
9.3.5.2.2.3 Japan: Colorectal Cancer Market, by Imaging Type - 2019- 2028 (US$ Million)
9.3.5.2.3 Japan: Colorectal Cancer Market Revenue and Forecast To 2028, By End Users (US$ Million)
9.3.5.3 India Colorectal Cancer Market Revenue And Forecasts To 2028 (US$ Million)
9.3.5.3.1 India Colorectal Cancer Market Revenue And Forecasts To 2028 (US$ Million)
9.3.5.3.2 India: Colorectal Cancer Market - Revenue and Forecast to 2028, By Modality (US$ Million)
9.3.5.3.2.1 India: Colorectal Cancer Market, by Diagnosis Type - 2019 - 2028 (US$ Million)
9.3.5.3.2.2 India: Colorectal Cancer Market, by Therapy Type - 2019- 2028 (US$ Million)
9.3.5.3.2.2.1. India: Colorectal Cancer Market, by Chemotherapy - 2019- 2028 (US$ Million)
9.3.5.3.2.2.2. India: Colorectal Cancer Market, by Immunotherapy - 2019- 2028 (US$ Million)
9.3.5.3.2.3 India: Colorectal Cancer Market, by Imaging Type - 2019- 2028 (US$ Million)
9.3.5.3.3 India: Colorectal Cancer Market Revenue and Forecast To 2028, By End Users (US$ Million)
9.3.5.4 South Korea Colorectal Cancer Market Revenue And Forecasts To 2028 (US$ Million)
9.3.5.4.1 South Korea Colorectal Cancer Market Revenue And Forecasts To 2028 (US$ Million)
9.3.5.4.2 South Korea: Colorectal Cancer Market - Revenue and Forecast to 2028, By Modality (US$ Million)
9.3.5.4.2.1 South Korea: Colorectal Cancer Market, by Diagnosis Type - 2019 - 2028 (US$ Million)
9.3.5.4.2.2 South Korea: Colorectal Cancer Market, by Therapy Type - 2019- 2028 (US$ Million)
9.3.5.4.2.2.1. South Korea: Colorectal Cancer Market, by Chemotherapy - 2019- 2028 (US$ Million)
9.3.5.4.2.2.2. South Korea: Colorectal Cancer Market, by Immunotherapy - 2019- 2028 (US$ Million)
9.3.5.4.2.3 South Korea: Colorectal Cancer Market, by Imaging Type - 2019- 2028 (US$ Million)
9.3.5.4.3 South Korea: Colorectal Cancer Market Revenue and Forecast To 2028, By End Users (US$ Million)
9.3.5.5 Australia Colorectal Cancer Market Revenue And Forecasts To 2028 (US$ Million)
9.3.5.5.1 Australia Colorectal Cancer Market Revenue And Forecasts To 2028 (US$ Million)
9.3.5.5.2 Australia: Colorectal Cancer Market - Revenue and Forecast to 2028, By Modality (US$ Million)
9.3.5.5.2.1 Australia: Colorectal Cancer Market, by Diagnosis Type - 2019 - 2028 (US$ Million)
9.3.5.5.2.2 Australia: Colorectal Cancer Market, by Therapy Type - 2019- 2028 (US$ Million)
9.3.5.5.2.2.1. Australia: Colorectal Cancer Market, by Chemotherapy - 2019- 2028 (US$ Million)
9.3.5.5.2.2.2. Australia: Colorectal Cancer Market, by Immunotherapy - 2019- 2028 (US$ Million)
9.3.5.5.2.3 Australia: Colorectal Cancer Market, by Imaging Type - 2019- 2028 (US$ Million)
9.3.5.5.3 Australia: Colorectal Cancer Market Revenue and Forecast To 2028, By End Users (US$ Million)
9.3.5.6 Rest of Asia Pacific: Colorectal Cancer Market Revenue and Forecast to 2028 (US$ Million)
9.3.5.6.1 Overview
9.3.5.6.2 Rest of Asia Pacific: Colorectal Cancer Market Revenue and Forecasts to 2028 (US$ Million)
9.3.5.6.3 Rest of Asia Pacific:: Colorectal Cancer Market - Revenue and Forecast to 2028, By Modality (US$ Million)
9.3.5.6.3.1 Rest of Asia Pacific:: Colorectal Cancer Market, by Diagnosis Type - 2019 - 2028 (US$ Million)
9.3.5.6.3.2 Rest of Asia Pacific:: Colorectal Cancer Market, by Therapy Type - 2019- 2028 (US$ Million)
9.3.5.6.3.2.1. Rest of Asia Pacific:: Colorectal Cancer Market, by Chemotherapy - 2019- 2028 (US$ Million)
9.3.5.6.3.2.2. Rest of Asia Pacific:: Colorectal Cancer Market, by Immunotherapy - 2019- 2028 (US$ Million)
9.3.5.6.3.3 Rest of Asia Pacific:: Colorectal Cancer Market, by Imaging Type - 2019- 2028 (US$ Million)
9.3.5.6.4 Rest of Asia Pacific:: Colorectal Cancer Market Revenue and Forecast To 2028, By End Users (US$ Million)
9.4 Middle East & Africa Colorectal Cancer Market Revenue and Forecasts to 2028
9.4.1 Overview
9.4.2 Middle East & Africa Colorectal Cancer Market Revenue And Forecasts To 2028 (US$ Million)
9.4.3 Middle East & Africa: Colorectal Cancer Market - Revenue and Forecast to 2028, By Modality (US$ Million)
9.4.3.1 Middle East & Africa: Colorectal Cancer Market, by Diagnosis Type - 2019 - 2028 (US$ Million)
9.4.3.2 Middle East & Africa: Colorectal Cancer Market, by Therapy Type - 2019- 2028 (US$ Million)
9.4.3.2.1 Middle East & Africa: Colorectal Cancer Market, by Chemotherapy - 2019- 2028 (US$ Million)
9.4.3.2.2 Middle East & Africa: Colorectal Cancer Market, by Immunotherapy - 2019- 2028 (US$ Million)
9.4.3.3 Middle East & Africa: Colorectal Cancer Market, by Imaging Type - 2019- 2028 (US$ Million)
9.4.4 Middle East & Africa: Colorectal Cancer Market Revenue and Forecast To 2028, By End Users (US$ Million)
9.4.5 Middle East & Africa Colorectal Cancer Market Revenue and Forecasts to 2028, By Country (%)
9.4.5.1 UAE Colorectal Cancer Market Revenue And Forecasts To 2028 (US$ Million)
9.4.5.1.1 UAE Colorectal Cancer Market Revenue And Forecasts To 2028 (US$ Million)
9.4.5.1.2 UAE: Colorectal Cancer Market - Revenue and Forecast to 2028, By Modality (US$ Million)
9.4.5.1.2.1 UAE: Colorectal Cancer Market, by Diagnosis Type - 2019 - 2028 (US$ Million)
9.4.5.1.2.2 UAE: Colorectal Cancer Market, by Therapy Type - 2019- 2028 (US$ Million)
9.4.5.1.2.2.1. UAE: Colorectal Cancer Market, by Chemotherapy - 2019- 2028 (US$ Million)
9.4.5.1.2.2.2. UAE: Colorectal Cancer Market, by Immunotherapy - 2019- 2028 (US$ Million)
9.4.5.1.2.3 UAE: Colorectal Cancer Market, by Imaging Type - 2019- 2028 (US$ Million)
9.4.5.1.3 UAE: Colorectal Cancer Market Revenue and Forecast To 2028, By End Users (US$ Million)
9.4.5.2 Saudi Arabia Colorectal Cancer Market Revenue And Forecasts To 2028 (US$ Million)
9.4.5.2.1 Saudi Arabia Colorectal Cancer Market Revenue And Forecasts To 2028 (US$ Million)
9.4.5.2.2 Saudi Arabia: Colorectal Cancer Market - Revenue and Forecast to 2028, By Modality (US$ Million)
9.4.5.2.2.1 Saudi Arabia: Colorectal Cancer Market, by Diagnosis Type - 2019 - 2028 (US$ Million)
9.4.5.2.2.2 Saudi Arabia: Colorectal Cancer Market, by Therapy Type - 2019- 2028 (US$ Million)
9.4.5.2.2.2.1. Saudi Arabia: Colorectal Cancer Market, by Chemotherapy - 2019- 2028 (US$ Million)
9.4.5.2.2.2.2. Saudi Arabia: Colorectal Cancer Market, by Immunotherapy - 2019- 2028 (US$ Million)
9.4.5.2.2.3 Saudi Arabia: Colorectal Cancer Market, by Imaging Type - 2019- 2028 (US$ Million)
9.4.5.2.3 Saudi Arabia: Colorectal Cancer Market Revenue and Forecast To 2028, By End Users (US$ Million)
9.4.5.3 South Africa Colorectal Cancer Market Revenue And Forecasts To 2028 (US$ Million)
9.4.5.3.1 South Africa Colorectal Cancer Market Revenue And Forecasts To 2028 (US$ Million)
9.4.5.3.2 South Africa: Colorectal Cancer Market - Revenue and Forecast to 2028, By Modality (US$ Million)
9.4.5.3.2.1 South Africa: Colorectal Cancer Market, by Diagnosis Type - 2019 - 2028 (US$ Million)
9.4.5.3.2.2 South Africa: Colorectal Cancer Market, by Therapy Type - 2019- 2028 (US$ Million)
9.4.5.3.2.2.1. South Africa: Colorectal Cancer Market, by Chemotherapy - 2019- 2028 (US$ Million)
9.4.5.3.2.2.2. South Africa: Colorectal Cancer Market, by Immunotherapy - 2019- 2028 (US$ Million)
9.4.5.3.2.3 South Africa: Colorectal Cancer Market, by Imaging Type - 2019- 2028 (US$ Million)
9.4.5.3.3 South Africa: Colorectal Cancer Market Revenue and Forecast To 2028, By End Users (US$ Million)
9.4.5.4 Rest of Middle East and Africa: Colorectal Cancer Market Revenue and Forecasts to 2028 (US$ Million)
9.4.5.4.1 Overview
9.4.5.4.2 Rest of Middle East and Africa: Colorectal Cancer Market Revenue and Forecasts to 2028 (US$ Million)
9.4.5.4.3 Rest of Middle East and Africa:: Colorectal Cancer Market - Revenue and Forecast to 2028, By Modality (US$ Million)
9.4.5.4.3.1 Rest of Middle East and Africa:: Colorectal Cancer Market, by Diagnosis Type - 2019 - 2028 (US$ Million)
9.4.5.4.3.2 Rest of Middle East and Africa:: Colorectal Cancer Market, by Therapy Type - 2019- 2028 (US$ Million)
9.4.5.4.3.2.1. Rest of Middle East and Africa:: Colorectal Cancer Market, by Chemotherapy - 2019- 2028 (US$ Million)
9.4.5.4.3.2.2. Rest of Middle East and Africa:: Colorectal Cancer Market, by Immunotherapy - 2019- 2028 (US$ Million)
9.4.5.4.3.3 Rest of Middle East and Africa:: Colorectal Cancer Market, by Imaging Type - 2019- 2028 (US$ Million)
9.4.5.4.4 Rest of Middle East and Africa:: Colorectal Cancer Market Revenue and Forecast To 2028, By End Users (US$ Million)
9.5 South and Central America: Colorectal Cancer Market
9.5.1 Overview
9.5.2 South and Central America: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
9.5.3 South and Central America: Colorectal Cancer Market - Revenue and Forecast to 2028, By Modality (US$ Million)
9.5.3.1 South and Central America: Colorectal Cancer Market, by Diagnosis Type - 2019 - 2028 (US$ Million)
9.5.3.2 South and Central America: Colorectal Cancer Market, by Therapy Type - 2019- 2028 (US$ Million)
9.5.3.2.1 South and Central America: Colorectal Cancer Market, by Chemotherapy - 2019- 2028 (US$ Million)
9.5.3.2.2 South and Central America: Colorectal Cancer Market, by Immunotherapy - 2019- 2028 (US$ Million)
9.5.3.3 South and Central America: Colorectal Cancer Market, by Imaging Type - 2019 - 2028 (US$ Million)
9.5.4 South and Central America: Colorectal Cancer Market - Revenue and Forecast to 2028, By End User (US$ Million)
9.5.5 South and Central America: Colorectal Cancer Market Share, by Country (2022 & 2028) (%)
9.5.5.1 Brazil: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
9.5.5.1.1 Brazil: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
9.5.5.1.2 Brazil: Colorectal Cancer Market - Revenue and Forecast to 2028, By Modality (US$ Million)
9.5.5.1.2.1 Brazil: Colorectal Cancer Market, by Diagnosis Type - 2019 - 2028 (US$ Million)
9.5.5.1.2.2 Brazil: Colorectal Cancer Market, by Therapy Type - 2019- 2028 (US$ Million)
9.5.5.1.2.2.1. Brazil: Colorectal Cancer Market, by Chemotherapy - 2019- 2028 (US$ Million)
9.5.5.1.2.2.2. Brazil: Colorectal Cancer Market, by Immunotherapy - 2019- 2028 (US$ Million)
9.5.5.1.2.3 Brazil: Colorectal Cancer Market, by Imaging Type - 2019 - 2028 (US$ Million)
9.5.5.1.3 Brazil: Colorectal Cancer Market - Revenue and Forecast to 2028, By End Users (US$ Million)
9.5.5.2 Argentina: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
9.5.5.2.1 Argentina: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
9.5.5.2.2 Argentina: Colorectal Cancer Market - Revenue and Forecast to 2028, By Modality (US$ Million)
9.5.5.2.2.1 Argentina: Colorectal Cancer Market, by Diagnosis Type - 2019 - 2028 (US$ Million)
9.5.5.2.2.2 Argentina: Colorectal Cancer Market, by Therapy Type - 2019- 2028 (US$ Million)
9.5.5.2.2.2.1. Argentina: Colorectal Cancer Market, by Chemotherapy - 2019- 2028 (US$ Million)
9.5.5.2.2.2.2. Argentina: Colorectal Cancer Market, by Immunotherapy - 2019- 2028 (US$ Million)
9.5.5.2.2.3 Argentina: Colorectal Cancer Market, by Imaging Type - 2019 - 2028 (US$ Million)
9.5.5.2.3 Argentina: Colorectal Cancer Market - Revenue and Forecast to 2028, By End Users (US$ Million)
9.5.5.3 Rest of South and Central America: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
9.5.5.3.1 Rest of South and Central America: Colorectal Cancer Market - Revenue and Forecast to 2028 (US$ Million)
9.5.5.3.2 Rest of South and Central America: Colorectal Cancer Market - Revenue and Forecast to 2028, By Modality (US$ Million)
9.5.5.3.2.1 Rest of South and Central America: Colorectal Cancer Market, by Diagnosis Type - 2019 - 2028 (US$ Million)
9.5.5.3.2.2 Rest of South and Central America: Colorectal Cancer Market, by Therapy Type - 2019- 2028 (US$ Million)
9.5.5.3.2.2.1. Rest of South and Central America: Colorectal Cancer Market, by Chemotherapy - 2019- 2028 (US$ Million)
9.5.5.3.2.2.2. Rest of South and Central America: Colorectal Cancer Market, by Immunotherapy - 2019- 2028 (US$ Million)
9.5.5.3.2.3 Rest of South and Central America: Colorectal Cancer Market, by Imaging Type - 2019 - 2028 (US$ Million)
9.5.5.3.3 Rest of South and Central America: Colorectal Cancer Market - Revenue and Forecast to 2028, By End Users (US$ Million)
10. Impact of COVID-19 Pandemic on Geographic Regions
10.1 North America: Impact Assessment of COVID-19 Pandemic
10.2 Europe: Impact Assessment of COVID-19 Pandemic
10.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic
10.4 Middle East and Africa: Impact Assessment of COVID-19 Pandemic
10.5 South and Central America: Impact Assessment of COVID-19 Pandemic
11. Global Colorectal Cancer Market - Industry Landscape
11.1 Overview
11.2 Growth Strategies In The Colorectal Cancer Market, 2022-2028
11.3 Organic Developments
11.3.1 Overview
11.3.2 Organic Growth Strategies In The Colorectal Cancer Market, 2022-2028
11.4 Inorganic Developments
11.4.1 Overview
11.4.2 Inorganic Growth Strategies In The Colorectal Cancer Market, 2022-2028
Samples
LOADING...
Companies Mentioned
- Amgen Inc.
- Bruker Corporation
- Epigenomics AG
- Clinical Genomics Technologies Pty Ltd.
- VolitionRx Limited
- Novigenix SA
- F. Hoffmann-La Roche AG
- Abbott
- EDP Biotech
- Quest Diagnostics
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 259 |
| Published | June 2022 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 18619.3 Million |
| Forecasted Market Value ( USD | $ 24078.5 Million |
| Compound Annual Growth Rate | 3.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
